Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer.

Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer. Oncol Lett. 2020 Nov;20(5):261 Authors: Delgado-Balderas JR, Gallardo-Blanco HL, Yee-De León JF, Rivas-Estilla AM, Soto-García B, Aráiz-Hernández D, Garza-Guajardo R, Náñez-Marín M, Hernández-Barajas D, García-Bailón AM, Vízcarra-Mata G, Ocaña-Munguía MA, Gómez-Guerra LS, Sánchez-Domínguez CN Abstract The presence of the genetic variants of the steroid 5-alpha reductase 2 enzyme, which is encoded by the SRD5A2 gene, has been associated with an increased risk of developing prostate cancer among certain ethnic groups. However, these molecular studies have not been conducted on the Mexican population. The analysis of the genetic variants, rs9282858 and rs523349, was performed in 101 males with prostate cancer and 100 healthy controls classified as males without prostate abnormalities (n=60) and males with benign prostatic hyperplasia (n=40), to identify a probable association with this cancer type in the Northeast Mexican population. An association was identified between prostate cancer and biomass exposure [P=0.012; odds ratio (OR), 2.89; confidence interval (CI)=1.21-6.88] and tobacco use (P=0.028; OR=1.88; CI=1.07-3.31), while no association was observed between cancer development and the rs9282858 variant, or between a protective effect and the rs523349 variant. Notably, an association was identifie...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research